Ticker brief

VRTX VERTEX PHARMACEUTICALS INC

Consumer, Non-cyclical · Biotechnology

last close
$541.69
1 day
-1.1%
14 days
+7.1%
mkt cap
$134.0B
signals 14d
19
authors 14d
16
crowd 14d
+1.6σ
Options inteloptions-surface reads · latest available day per source
metricreadingcontext
IV — ATM 30d33% mid · 62 pctile own 1yIV/HV 0.86× (as of 2026-08-06)
Skew — 25Δ RR 30d+0.021 99 pctile own 1ycalls bid vs puts (call skew rich)
Net dealer OI (NDOI)+0.51 elevated5-session Δ +0.15 (as of 2026-07-06)
OI alarmquietlast alarm 2026-05-05 (z=2.1)
Sentiment — last 14 days
daily mean sentiment, 2026-08-18 → 2026-08-28 · now +0.00 (−1 bearish … +1 bullish)
Who spoke16
authorgradetrader scoresignalsmean sent
@TravisBiziorekC-2.393+0.58
@PortfolioBossC-1.862+0.47
@DivIncomeBcastC+0.271+0.45
@MarketMaestro1C-2.461+0.55
@KunnuInvestsC-1.521+0.70
@hughesanalyticsA-0.801+0.40
@VladBastionB-1.801+0.35
@ShakePryzby1B+0.061+0.15
@KeithTradeSmithC+0.251+0.55
@MartyCharginC-0.271+0.40
@PersimmonTIA-0.571+0.30
@AsafNaamaniC-3.381+0.35
@BornInvestorC+0.161+0.15
@SuEricGPB+2.071+0.70
@MorningstarIncB+0.801-0.40
@TalkMarketsC·1+0.00
Recent signals19of 19 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-08-28@TalkMarkets+0.00Frames a valuation and growth-efficiency divergence between VRTX and REGN.
2026-08-25@MorningstarInc-0.40Morningstar analysts now rate VRTX and REGN as expensive and newly overvalued.-2.0%
2026-08-25@TravisBiziorek+0.50Closed VRTX for a win while retaining substantial MRNA exposure and remaining bullish on VRTX.-2.0%
2026-08-25@SuEricGP+0.70Recaps a 44% VRTX gain from $380 to $540 and says the rating is now hold.-2.0%
2026-08-23@BornInvestor+0.15Historical recap of VRTX's 1999 catalyst, valuation peak, later trough and current market capitalization.-1.2%
2026-08-23@AsafNaamani+0.35Reports ETF performance and identifies $40.48 as a breakout level for further upside.-1.2%
2026-08-23@PersimmonTI+0.30Predicts BBIO could become the next VRTX if it remains independent.-1.2%
2026-08-23@MartyChargin+0.40Enthusiastically frames four large drug companies as sector leaders.-1.2%
2026-08-23@KeithTradeSmith+0.55Argues biotech is an underappreciated bull market supported by momentum, valuations and AI.-1.2%
2026-08-22@PortfolioBoss+0.45Claims capital is flowing into Bitcoin and a broad pharmaceutical basket.-1.2%
2026-08-21@ShakePryzby1+0.15Sees a potential biotech leadership cycle and highlights CRSP as a breakout candidate.-1.2%
2026-08-21@TravisBiziorek+0.80Buy VRTX; its weekly chart looks exceptionally strong. — Directly urges buying VRTX based on a strong weekly setup.-1.2%
2026-08-21@VladBastion+0.35Ranks healthcare momentum leaders and highlights renewed interest in beaten-down CRL.-1.2%
2026-08-20@hughesanalytics+0.40Identifies these symbols as strengthening while market rotation broadens beyond semiconductors.+0.3%
2026-08-19@TravisBiziorek+0.45Reports VRTX achieving an all-time closing high.-1.9%
2026-08-19@KunnuInvests+0.70Calls VRTX a strong monthly breakout after consolidation.-1.9%
2026-08-19@MarketMaestro1+0.55Monthly chart is described as positioned for a breakout.-1.9%
2026-08-18@PortfolioBoss+0.50Calls a bull market and says capital is rotating into biotech.+2.6%
2026-08-18@DivIncomeBcast+0.45Shares Grok's decade-long sector picks; ticker cap retains the first two baskets.+2.6%

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.